Dose Uniformity & Emitted Dose Testing

Aerosol Science

Compendial collection trains, controlled flow and actuation, and HPLC / ELISA / qPCR-ddPCR quantitation — emitted dose, dose uniformity, and variability contributors documented per study.

Purpose & when to use

Dose Uniformity and Emitted Dose (DU / ED) testing measures how much active or tracer reaches a defined collection point per actuation, and how consistent that delivery stays shot-to-shot and device-to-device. Compendial collection trains, controlled flow and actuation, and HPLC / ELISA / qPCR-ddPCR quantitation deliver per-shot dose and variability metrics aligned to USP <601>, USP <1601>, and FDA MDI / DPI / nasal-spray guidances. DU / ED is foundational for:

Per-actuation emitted dose and dose-uniformity packages for MDIs, DPIs, nebulizers, and nasal sprays — submission-grade datasets aligned to USP <601>, USP <1601>, and FDA MDI / DPI / nasal guidances.
In vitro bioequivalence and comparability packages for predicate and lifecycle changes — dose-uniformity trending and statistical equivalence framing under FDA bioequivalence and ICH Q5E guidance.
Formulation and component-tolerance screening during development — fast shot-to-shot dose checks for valve, pump, nozzle, or excipient changes under FDA development-stage CMC guidance.
Drift investigation across fill level, aging, storage conditions, and device wear — supports stability and shelf-life packages under USP <601> and ICH Q1A framing.
Variability root-cause investigation when emitted dose exceeds spec — pairs with PSD and high-speed imaging under ICH Q9 quality-risk framing to isolate actuation, leakage, or component contributors.

Use DU / ED testing when emitted dose or uniformity drives the regulatory or commercial question — submission packages, predicate comparisons, stability programs, or formulation iteration — and you need quantitation tied to a controlled actuation, flow, and collection setup that stands up under inspection.

Built for inhalation, intranasal, and oral drug delivery

DU / ED testing spans the device classes where per-actuation dose is the central performance attribute — pharmaceutical inhalation and intranasal devices plus oral spray products under a documented quality system.

MDIMetered-dose inhalers
DPIDry-powder inhalers
NebulizerLiquid aerosol generators
Nasal sprayIntranasal delivery
Oral spraySublingual and topical-oral

Instrumentation & measurement ranges

Platform selection follows the device class, the active, and the regulatory frame — each component is scoped at study planning and logged in the report.

1 – 100 L/mininduction-port-flow

Compendial collection trains (USP-aligned fixtures)

USP-aligned induction port, mouthpiece adapters, and nasal / oral interfaces — compliant geometry for emitted-dose collection across MDI, DPI, nebulizer, and nasal-spray devices.

1 – 100 L/mincontrolled-flow

Mass-flow controllers and inhalation profile rigs

Calibrated flow control for steady-state and breathing-simulation profiles — pinned by mass-flow controllers and logged shot-by-shot for traceable per-actuation conditions.

0.1 – 100 Nactuation-force

Stepper-driven actuation fixtures

Controlled stroke, force, and timing under stepper control — manual, pneumatic, or mechanical fixtures sized to mimic patient or operator use across the actuation envelope.

0.1 – 1000 µgper-actuation

Analytical quantitation suite (HPLC, ELISA, qPCR / ddPCR)

HPLC for small-molecule actives, ELISA for protein analytes, and qPCR / ddPCR for nucleic-acid actives — assay matched to the active and matrix on a per-study basis.

Test method options

Method	Strengths	Tradeoff	Aligned with
Compendial-aligned emitted dose and uniformity (USP <601> / <1601>)	Submission-grade per-actuation dose and uniformity datasets — the canonical compendial package under USP <601> and USP <1601>. Documented acceptance logic and statistical framing for FDA MDI / DPI / nasal submissions and lifecycle change packages.	Strict fixture, flow, and assay control overhead — best when the device is locked and the data is filing-bound.	USP <601>USP <1601>FDA MDI / DPI / nasal
Development screening for dose consistency	Faster iteration with reduced replicates — supports formulation, valve, pump, and component-tolerance screening under FDA development-stage CMC framing. Same fixtures as the compendial method but acceptance bands tuned for iteration speed over filing rigor — design-team-friendly cadence.	May require follow-on confirmation under compendial conditions before filing — bridge to the regulator-aligned method when the program approaches submission.	FDA MDI / DPI / nasal
Robustness study (actuation profile, flow, environment)	Surfaces sensitivity to actuation force, flow profile, fill level, and temperature — defines the use-condition envelope where dose stays in spec. Output feeds change-control packages and predicate comparisons under USP <601> and FDA MDI / DPI / nasal change-control framing.	More conditions per study increase sample count and analyst time — scope tightly to the variables that drive the decision.	USP <601>FDA MDI / DPI / nasal
Troubleshooting and root-cause investigation	Pinpoints sources of variability — valve, pump, viscosity, leakage, or actuator wear — using paired methods and instrument records. Often paired with PSD or plume geometry under ICH Q9 quality-risk framing so the investigation closes with a defensible CAPA package.	Iterative by nature — schedule unpredictability is higher than fixed-protocol studies; budget for two or three investigation rounds.	ICH Q9

Setup configurations

Every DU / ED study runs on a configuration matched to the device, the active, and the regulatory frame. Fit-for-purpose setup balances compendial rigor — controlled flow, actuation, and traceable collection — with practical realities of the device under test. The dimensions below are the levers we set at study planning:

Device interfaces

Mouthpiece adapters, induction ports, nasal and oral interfaces — geometry matched to the device class and the compendial frame under test.

Flow & actuation profiles

Mass-flow-controlled flow profiles, stepper-driven actuation force and stroke, and defined shot schedules — every parameter logged shot-by-shot.

Sample numbers

Replicates per device and across devices — power sized to declared shot-to-shot and device-to-device variability with documented statistical framing.

Media & handling

Collection-media selection, extraction-solvent compatibility, and documented storage for collected fractions and analytical samples.

Calibration & verification

Mass-flow controllers, actuation force, and assay calibration verified against traceable standards before each campaign and between condition blocks.

Methods anchored to the standards that matter

Every DU / ED study runs inside a documented quality system aligned to inhalation, intranasal, and oral-spray regulatory frames. The four anchors below define the data contract carried through to §7 outputs.

ISO 17025AccreditedTesting-laboratory competence — documented methods, calibration traceability, and uncertainty contributors.
USP <601>AccreditedAerosols, nasal sprays, MDIs, and DPIs — performance quality tests including delivered-dose uniformity.
USP <1601>AlignedProducts for nebulization — characterization tests including aerosol output and dose.
FDA MDI / DPI / nasalAlignedChemistry, manufacturing, and controls plus bioequivalence framing for inhalation and intranasal submissions.

Key data outputs & reporting

Every DU / ED study delivers documented per-actuation dose, uniformity statistics, and the underlying datasets — emitted dose per shot, summary statistics (mean, SD, CV), dose-vs-shot trending where applicable, and traceable QA / QC controls — formatted for submission packages, change-control documentation, or development decisions. The deliverables below cover the standard report; comparability programs, predicate studies, and stability time-courses get extended artifacts beneath the table.

Primary outputs

Emitted dose per actuation and summary statistics across shots, devices, and lots (mean, SD, CV, condition deltas).
Dose-uniformity trending across shot number, fill level, or canister-life position with predefined acceptance bands.
Assay calibration, recovery, and uncertainty contributors documented alongside results for inspection-readiness.

Deliverables

#	Format	Contents
01	PDF report	Methods, controls, statistical framing, and acceptance logic.
02	CSV / XLSX datasets	Per-shot dose, replicate statistics, and condition deltas.
03	Figures	Dose-vs-shot plots, condition overlays, and distribution charts for internal review and submission appendices.

Extended deliverables · multi-arm comparability · stability · predicate studies

Comparability appendix — Side-by-side dose-vs-shot overlays plus statistical equivalence tests per ICH Q1E or product-specific predicate framing.
Stability time-course pack — Emitted-dose and uniformity trends across timepoints with predefined OOT criteria flagged per ICH Q1A.
Method-development notes — Fixture, actuation, and assay-selection rationale plus uncertainty contributors — for submission cover letters and inspection readiness.

QA / QC & data integrity

Every DU / ED study ships with a documented QA / QC envelope sized to the method plan — controls and verifications calibrated to the regulatory frame, the analytical chemistry, and the decision the data supports. The checks below run alongside dose collection, audited under our ISO 17025 quality system and traceable from sample receipt through final result. Recovery, system suitability, and matrix-effect checks get added when the assay demands them.

Blanks and background controls for collection media plus fixture-residue checks before each campaign.

Replicate measurements and repeat runs to quantify shot-to-shot and device-to-device precision.

Assay controls — calibration standards, system suitability per assay, and spike-recovery on matrix-challenging analytes.

Flow and actuation verification logs alongside captured doses with mass-flow controller calibration records.

Chain of custody from sample receipt through analysis and final reporting.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)

17025Accredited testing

900+Studies Performed

17+Years in operation

300+Clients supported

Common questions

Quick answers to the questions inhalation, intranasal, and oral-spray teams ask most often when scoping a dose uniformity or emitted dose study — assay selection, fixture choice, replicate plans, comparability framing, and deliverables. The answers below are starting points, not protocols; reach out if your device, active, or regulatory frame doesn't match what's here, since most DU / ED studies need at least one custom configuration choice.

Q.Is emitted dose the same as delivered dose?

A.Emitted dose is what we collect at the device outlet through a defined compendial fixture. Delivered dose can require additional anatomical models, breathing simulations, or in vivo work — we scope the right collection point during study planning.

Q.Can you quantify biologics or nucleic-acid actives?

A.Yes. We run ELISA for protein analytes and qPCR / ddPCR for nucleic-acid actives, with assay controls, system suitability, and recovery documented alongside results — same compendial fixtures, assay tuned to the active.

Q.How many actuations should be tested?

A.It depends on device output, assay sensitivity, and the comparability target. Submission packages typically run n=10+ devices with replicates across canister positions; development screening runs leaner. We plan shot counts at study setup.

Q.What drives dose variability most often?

A.Actuation force and timing, component tolerances (valve, pump, nozzle), leakage, and formulation viscosity are the common contributors. We pin flow and actuation, log each shot, and document assay recovery so the comparison stays interpretable.

Q.What do you deliver?

A.A PDF report with methods, controls, statistical framing, and acceptance logic; CSV / XLSX datasets for per-shot dose and replicate statistics; and figures (dose-vs-shot, condition overlays, distributions) suitable for internal review and submission appendices.

Standards & guidance

DU / ED studies at ARE Labs run aligned to the regulatory and consensus standards governing inhalation, intranasal, and oral-spray dose delivery. Where we hold third-party accreditation for a scope, methods are documented as accredited (ISO 17025, USP <601>); where the standard is followed but not formally accredited, methods are aligned or conformant where applicable. The cards below list the standards most often relevant to DU / ED packages.

Inhalation & Drug Delivery - Accredited

Related services & devices

Service